LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
The annual report highlights that 2025 was a pivotal year for LIXTE, as it focused on advancing its lead compound LB-100, a first-in-class clinical PP2A inhibitor. LB-100 has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The company is currently conducting proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
In addition to its clinical progress, LIXTE completed the acquisition of Liora Technologies Europe Ltd., which is pioneering electronically controlled proton therapy systems for treating tumors. Liora's proprietary LiGHT System is believed to provide significant advantages over currently available technologies for proton therapy. This acquisition expands LIXTE's portfolio beyond small-molecule inhibitors into advanced medical devices.
Financially, LIXTE raised over $11 million to strengthen its balance sheet, ensuring it has the resources to support ongoing clinical trials and operational growth. The company's comprehensive patent portfolio covers its novel approach to cancer biology, termed activation lethality, which is advancing a new treatment paradigm in oncology.
For more details, the full press release is available at https://ibn.fm/LP6QH. The company also encourages readers to review its filings with the SEC, including the Annual Report on Form 10-K, for a complete understanding of its business and risks.
